On Monday, Shares of JPMorgan Chase & Co. (NYSE:JPM), lost -5.27% to $60.25, hitting its lowest level.
JPMorgan Chase & Co. declared the appointment of stepped down four-star General Raymond T. Odierno, former Chief of Staff of the U.S. Army, to a senior advisory capacity at the firm, effective September 1st. General Odierno will provide planned advice and global insights to Chairman and CEO Jamie Dimon, the Board of Directors and members of the Operating Committee on a broad range of issues counting international planning and country risk analysis, technology, operations and the rapidly evolving issues of physical and cyber security. He will also provide his expertise to assist structure and carry out the firm’s leadership development training programs and assist on other leadership and workforce development issues.
Additionally, General Odierno will represent JPMorgan Chase through engagement with clients, government officials and policy makers in the U.S. and internationally and will take part in the firm’s regional advisory groups in Europe, the Middle East, Africa, the Asia-Pacific region and Latin America. He will also advise on the firm’s cities initiatives, counting the Global Cities Initiative and New Skills at Work, meeting with mayors and other public officials to provide them with expert insight and advice that will assist respective metropolitan areas thrive in the global economy and representing the firm in select events and conferences with JPMorgan’s partnership organizations.
JPMorgan Chase & Co. provides various financial services worldwide. The company operates through four segments: Consumer & Community Banking, Corporate & Investment Bank, Commercial Banking, and Asset Administration.
Shares of Opko Health, Inc. (NYSE:OPK), declined -13.92% to $10.33, during its last trading session.
Opko Health declared that it has reached agreements with Stratose, Three Rivers Provider Network and Fortified Provider Network for testing services from OPKO Lab, counting the 4Kscore®Test, the only blood test that accurately identifies an individual patient’s risk for high-grade, aggressive cancer. The cumulative contracts, with some of the largest healthcare PPO network providers in the U.S., will give over 25 million people access to the testing services of OPKO Lab.
“These agreements demonstrate the value of the portfolio of testing services offered by OPKO Lab, counting the 4Kscore Test,” said David Okrongly, Ph.D., President of OPKO Diagnostics. “We are gratified at the growing acceptance by health plan customers of the value offered to patients and physicians by the 4Kscore Test and our other testing services. We look forward to providing these services to their network participants.”
OPKO Lab, a full service urological testing laboratory, is the provider of the 4Kscore Test. The 4Kscore Test is the only blood test that accurately identifies an individual patient’s risk for high-grade, aggressive cancer and is now comprised of in the NCCN 2015 Guidelines for Prostate Cancer Early Detection.
OPKO Health, Inc., a biopharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies in the United States and internationally. It operates through two segments, Pharmaceuticals and Diagnostics.
Finally, Applied Optoelectronics, Inc. (NASDAQ:AAOI), ended its last trade with -4.17% loss, and closed at $19.06.
Applied Optoelectronics declared the completion of its formerly-declared $40.0 million “at the market” stock offering. The company sold a total of 1,857,329 shares, raising net proceeds (after sales commissions) of $39.0 million.
“AOI has grown rapidly over the past two years and we plan to use the capital raised to assist us meet anticipated future demand in particular for our 100 Gbps transceivers and light engines,” commented Dr. Stefan Murry, AOI’s chief financial officer and chief strategy officer. “We are happy to have accomplished this offering and look forward to deploying these proceeds to fund expansion initiatives that assist support AOI’s long-term growth strategy.”
Applied Optoelectronics, Inc. designs and manufactures optical communications products for Internet data center, cable television (CATV), and fiber-to-the-home markets. It offers optical modules, optical transceivers, lasers, transmitters, and turn-key equipment, in addition to headend, node, and distribution equipment.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
